Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Wolinsky

Showing results (271-280 of 331) with videos related to

Pageof 34
Sort By:
The Journal of Clinical Investigation|June 17, 1998
Lack of strong immune selection pressure by the immunodominant, HLA-A*0201-restricted cytotoxic T lymphocyte response in chronic human immunodeficiency virus-1 infectionC Brander, K E Hartman, A K Trocha, et al.
AJNR. American Journal of Neuroradiology|February 18, 2006
Standardized MR imaging protocol for multiple sclerosis: Consortium of MS Centers consensus guidelinesJ H Simon, D Li, A Traboulsee, et al.
European Journal of Neurology|October 25, 2021
Cerebellar pathology and disability worsening in relapsing-remitting multiple sclerosis: A retrospective analysis from the CombiRx trialMaria Petracca, Gary Cutter, Sirio Cocozza, et al.
The Lancet. Neurology|January 28, 2014
Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trialChristian Confavreux, Paul O'Connor, Giancarlo Comi, et al.
Neurology|August 17, 1999
The contribution of magnetic resonance imaging to the diagnosis of multiple sclerosisF Fazekas, F Barkhof, M Filippi, et al.
Neurology|May 10, 2006
MRI T2 lesion burden in multiple sclerosis: a plateauing relationship with clinical disabilityD K B Li, U Held, J Petkau, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 1, 2013
Magnetic resonance imaging outcomes from a phase III trial of teriflunomideJerry S Wolinsky, Ponnada A Narayana, Flavia Nelson, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|August 23, 2017
Teriflunomide slows BVL in relapsing MS: A reanalysis of the TEMSO MRI data set using SIENAErnst-Wilhelm Radue, Till Sprenger, Laura Gaetano, et al.
Journal of Magnetic Resonance Imaging : JMRI|April 29, 2015
MR-derived cerebral spinal fluid hydrodynamics as a marker and a risk factor for intracranial hypertension in astronauts exposed to microgravityLarry A Kramer, Khader M Hasan, Ashot E Sargsyan, et al.
Journal of Magnetic Resonance Imaging : JMRI|November 22, 2016
Patient-specific 3D FLAIR for enhanced visualization of brain white matter lesions in multiple sclerosisRefaat E Gabr, Amol S Pednekar, Koushik A Govindarajan, et al.
Pageof 34

Showing results (271-280 of 331) with videos related to

Sort By:
Pageof 34
The Journal of Clinical Investigation|June 17, 1998
Lack of strong immune selection pressure by the immunodominant, HLA-A*0201-restricted cytotoxic T lymphocyte response in chronic human immunodeficiency virus-1 infectionC Brander, K E Hartman, A K Trocha, et al.
AJNR. American Journal of Neuroradiology|February 18, 2006
Standardized MR imaging protocol for multiple sclerosis: Consortium of MS Centers consensus guidelinesJ H Simon, D Li, A Traboulsee, et al.
European Journal of Neurology|October 25, 2021
Cerebellar pathology and disability worsening in relapsing-remitting multiple sclerosis: A retrospective analysis from the CombiRx trialMaria Petracca, Gary Cutter, Sirio Cocozza, et al.
The Lancet. Neurology|January 28, 2014
Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trialChristian Confavreux, Paul O'Connor, Giancarlo Comi, et al.
Neurology|August 17, 1999
The contribution of magnetic resonance imaging to the diagnosis of multiple sclerosisF Fazekas, F Barkhof, M Filippi, et al.
Neurology|May 10, 2006
MRI T2 lesion burden in multiple sclerosis: a plateauing relationship with clinical disabilityD K B Li, U Held, J Petkau, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 1, 2013
Magnetic resonance imaging outcomes from a phase III trial of teriflunomideJerry S Wolinsky, Ponnada A Narayana, Flavia Nelson, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|August 23, 2017
Teriflunomide slows BVL in relapsing MS: A reanalysis of the TEMSO MRI data set using SIENAErnst-Wilhelm Radue, Till Sprenger, Laura Gaetano, et al.
Journal of Magnetic Resonance Imaging : JMRI|April 29, 2015
MR-derived cerebral spinal fluid hydrodynamics as a marker and a risk factor for intracranial hypertension in astronauts exposed to microgravityLarry A Kramer, Khader M Hasan, Ashot E Sargsyan, et al.
Journal of Magnetic Resonance Imaging : JMRI|November 22, 2016
Patient-specific 3D FLAIR for enhanced visualization of brain white matter lesions in multiple sclerosisRefaat E Gabr, Amol S Pednekar, Koushik A Govindarajan, et al.
Pageof 34